This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Amicus' 'Transformative' Changes Look More Like Big Step Backward

Stocks in this article: FOLD GSK SNY BMRN

FOLD Chart

FOLD data by YCharts

Talk about a news dump. On Wednesday night, Amicus Therapeutics (FOLD - Get Report) announced 1) the loss of its biggest and most important drug development partner GlaxoSmthKline (GSK - Get Report); 2) the acquisition of Callidus Biopharma, a small, privately held orphan disease drug maker; 3) a corporate restructuring in which 14% of the company's employees were fired; 4) the resignation of its chief scientific officer; and 5) $40 million in new equity and debt financing.

Amicus CEO John Crowley heralded the changes as "transformative" and said the company was now stronger and better positioned to develop new enzyme replacement therapies for orphan diseases like Fabry and Pompe.

But Amicus shares didn't budge in Wednesday's after-hours trading session -- a sign investors weren't necessarily buying into Crowley's rosy interpretation of events. 

Investors might still be trying to figure out what tonight's "repositioning" really means. Here's one way of thinking about Amicus: If you haven't already written off Amigal, the company's lead drug for Fabry, then you should now that Glaxo bailed. And without Amigal, Amicus' pipeline reverts back to preclinical candidates for orphan diseases, which means the competitive gap between it and rivals Sanofi  (SNY - Get Report) and Biomarin Pharmaceuticals (BMRN - Get Report) has grown wider. 

Perhaps the best thing to be said about Amicus today is that with the stock down 53% in the past year and a $100 million market cap, investors haven't exactly been giving the company much credit for anything. 

You can read more about the restructuring of Amicus' Amigal agreement with Glaxo here and Amicus' acquisition of Callidus here.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs